Although we did not evaluate a number of PDX tumor lines large enough to have the power required to achieve a statistically supported conclusion, our results showed a trend: Those PDXs that expressed high levels of PD-L1 appeared to respond to the anti-PD-1 therapy.
← all excerpts
Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
1
—
—